

DOI: [10.4081/monaldi.2023.2619](https://doi.org/10.4081/monaldi.2023.2619)

Classification of chronic obstructive pulmonary disease as ABCD according to the GOLD 2011 and 2017 versions in patients at the University Medical Center in Ho Chi Minh City, Vietnam

Vinh Nguyen-Nhu,^{1,2} Lam-Phuoc Nguyen,¹ Sy Duong-Quy,^{3,4}
Pham Le An,^{1,5} Tri Bui-Minh⁵

¹Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam; ²Department of Respiratory Functional Exploration, University Medical Center, Ho Chi Minh City, Vietnam; ³Bio-Medical Research Center, Lam Dong Medical College, Da Lat, Vietnam; ⁴Hershey Medical Center, Penn State Medical College, Hershey, PA, USA; ⁵Grant Innovation Center, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam

Correspondence: Tri Bui-Minh, Grant Innovation Center, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam.
E-mail: buiminhtri17041992@gmail.com

Key words: chronic obstructive pulmonary disease, GOLD 2017 classification, university medical center, comparison, COPD treatment.

Supplementary Table 1. Percentage of the reclassified group in some studies.

Country	Year of research	Sample size	%C to %A (% change)	%D to %B (% change)	References
China	2019	1278	2.2-1.2 (1)	70.7-48.4 (22.3)	[9]
China	2017	1532	26.8-12 (14.9)	43-25.2 (17.8)	[7]
Korea	2018	1880	6.6-2.2 (4.4)	38.1-14.4 (22.4)	[12]
Taiwan	2018	1053	6.7-1.9 (4.8)	34.2-11.6 (22.6)	[10]
Japan	2018	1168	9.9-2.7 (7.2)	29.8-10 (19.8)	[11]
Switzerland	2018	571	10.9-5.1 (5.8)	36.1-19.3 (16.8)	[15]
Our study	2021	457	13.1-12 (1.1)	61.1-47.8 (13.3)	

Supplementary Table 2. Comparison of patients in different Global Initiative for Chronic Obstructive Lung Disease stages.

Subjects	Total	GOLD 1 n=36	GOLD 2 n=194	GOLD 3 n=190	GOLD 4 n=37	p-value
Age group, n (%)						<0.001
40-49	28 (6.1)	5 (13.9)	7 (3.61)	13 (6.84)	3 (8.11)	
50-59	102 (22.3)	6 (16.7)	38 (19.6)	44 (23.2)	14 (37.8)	
60-69	167 (36.5)	7 (19.4)	66 (34.0)	76 (40.0)	18 (48.6)	
>= 70	160 (35.0)	18 (50.0)	83 (42.8)	57 (30.0)	2 (5.41)	

GOLD, Global Initiative for Chronic Lung Disease.

Supplementary Table 3. Comparison of patients between low-risk group (A-B) and high-risk group (C-D) according to Global Initiative for Chronic Obstructive Lung Disease 2017 criteria.

Subjects	Low-risk group n=184	High-risk group n=273	p-value
Age (years), mean \pm SD	65.3 \pm 10.7	65.3 \pm 9.84	0.981
Age group, n (%)			0.063
40-49	13 (7.07)	15 (5.49)	
50-59	48 (26.1)	54 (19.8)	
60-69	54 (29.3)	113 (41.4)	
\geq 70	69 (37.5)	91 (33.3)	
Male, n(%)	173 (94.0)	260 (95.2)	0.567
BMI [°]	21.1 (4.62)	21.0 (5.22)	0.442
BMI classification, n(%)			0.683
Underweight	42 (22.8)	67 (24.5)	
Normale range	86 (46.7)	121 (44.3)	
Overweight	27 (14.7)	49 (17.9)	
Obese	29 (15.8)	36 (13.2)	
Dyspnoea, n (%)	138 (75.0)	232 (85.0)	0.011
Cough, n (%)	143 (77.7)	235 (86.1)	0.024
Sputum, n (%)	126 (68.5)	226 (82.8)	0.001
Wheezing, n (%)	115 (62.5)	219 (80.2)	<0.001
FVC [°]	73.0 (22.3)	67.0 (24.0)	<0.001
FEV1 [°]	56.0 (23.0)	45.0 (20.0)	<0.001
FEV1FVC [°]	56.0 (11.0)	52.0 (12.0)	<0.001
GOLD_therapy, n(%)			<0.001
LABA	70 (38.0)	10 (3.66)	
LABA + ICS	29 (15.8)	47 (17.2)	
LAMA	12 (6.52)	11 (4.03)	
LAMA + LABA	57 (31.0)	105 (38.5)	
LAMA + LABA + ICS	7 (3.80)	97 (35.5)	
SABA/ SABA + SAMA	9 (4.89)	3 (1.10)	

BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in the first second; LABA, long-acting β -agonists; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; SABA, short-acting β -agonists; SAMA, short-acting muscarinic antagonist; [°]non-normal distribution data were expressed as medians (interquartile range).